Grants

  • Development and characterization of improved materials derived from human adenoviruses to be used in gene therapy. Technology Foundation STW (LGN.3977)
    Principal investigators: Prof. dr. Dinko Valerio and Prof. dr. Rob C. Hoeben
  • Development of improved adenoviral vectors. Research Grant Crucell
    Principal investigator: Prof. dr. Rob C. Hoeben
  • Glia attenuated and receptor-targeted oncolytic adenoviral vectors for gene therapy of primary brain tumors. Dutch Cancer Society (DDHK 2001-2459)
    Principal investigators: dr. Peter A.E. Sillevis Smitt and Prof. dr. Rob C. Hoeben
  • Development and implementation of a lentiviral vector system (Matching-fund grant LUMC)
    Principle investigator: Prof. dr. Rob C. Hoeben
  • Development of transcriptionally targeted killer viruses as therapeutic tools. Eurogendis  (QLGA-CT-2000-60005)
    Contract Holder: Françoise Carlotti, Host: Prof. dr. Rob C. Hoeben
  • Characterization of TT virus: a recently identified widespread infectious agent of humans. Dutch ZonMW / Finnish Research Councel for Medicine. Travel grant (project 910-31-601).
    Applicants: Prof. dr. Rob C.Hoeben, Prof. dr. Klaus Hedman & Prof. dr. Maria Söderlund-Venermo (Helsinki)
  • Innovations in Clinical Gene Therapy: A Literature Study on Their Biosafety Implications. COGEM Exploratory Grant. Applicant Prof. dr. Rob C. Hoeben
  • GIANT: Gene therapy: An Integrated Approach to Neoplastic Treatment. FP6 Integrated project, EU  contract nr. 512087
  • Human islet cell formation from bone marrow- or cord blood-derived stem cells.  Diabetes Research Fund DFN 2005.00.0212. Principal investigators: Prof. dr. Rob C. Hoeben & Dr. Shoshan Knaan-Shanzer.
  • Protection of transplanted B-cells from autoimmunity and allo-reactive T cells through viral immune evasion strategies Diabetes Research Fund DFN 2007.00.0015. Principal investigators: Prof. dr. Emmanuel J. Wiertz, & Prof. Rob. C. Hoeben
  • Use of non-human Oncolytic viruses: A Literature Survey. COGEM  Exploratory Grant. Applicant Prof. dr. Rob C. Hoeben
  • New oncolytic viruses,  an Industry Grant. Principle investigator: Prof. dr. Rob C. Hoeben